Sep 24,2021

DarioHealth to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

DarioHealth Corp., a pioneer in the global digital therapeutics market, today announced that management will participate in a fireside chat during the Cantor Fitzgerald Virtual Global Healthcare Conference, which is being held September 27-30, 2021.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Sep 24,2021

Six Digital Health Technologies That Will Transform Diabetes

In this article, we highlight six areas of innovation that have the potential to reduce the burden of diabetes for individuals living with the condition and their families as well as provide measurable benefits for all stakeholders involved in diabetes care.

CLINICAL STUDY

#telehealth

View Analyst & Ambassador Comments
Go to original news
Sep 24,2021

Voluntis announces its results for the first half of 2021

Voluntis today announced its half-year results for 2021 as approved by the Board of Directors at its meeting today. The procedures for the limited review of the interim financial statements have been completed. The limited review report will be issued after verification of the half-year activity report. The half-year financial report will be published no later than October 1, 2021.

View Analyst & Ambassador Comments
Go to original news
Sep 27,2021

Nemaura Medical Announces Commercial Agreement with UK Licensee

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces that it has signed a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under terms of the deal, the CGM and sensors will be provided as Duo-Packs with prescription only medicines that are widely prescribed for people with Type 2 diabetes. Nemaura has previously placed order for 200,000 CGMs in anticipation of commercial ramp-up.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 28,2021

New Tu Salud Study Shows LifeScan’s OneTouch® Blood Glucose Meter and Spanish-Language Diabetes Management App Significantly Improved Diabetes Management for People with Diabetes in an Underserved Hispanic Population

LifeScan, a world leader in blood glucose monitoring, today announced findings from its Tu Salud (Your Health) clinical trial showing that using its OneTouch Verio Flex® meter with a Spanish-language version of its OneTouch Reveal® mobile application (app) led to significant and sustained improvement in diabetes management in people with diabetes and low numeracy and low literacy in an underserved Hispanic population. The study, conducted with LCH Health and Community Services, a Federally Qualified Health Center in Chester County, Pennsylvania, was published today in Diabetes Spectrum, a peer-reviewed journal of the American Diabetes Association.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Sep 28,2021

REAL-WORLD DATA SHOW ABBOTT'S FREESTYLE LIBRELINK APP USERS SPEND MORE TIME IN TARGET GLUCOSE RANGE COMPARED TO READER USERS

Abbott today announced new data recently published in the Journal of Diabetes Science and Technology demonstrating that people living with diabetes who use FreeStyle Libre's smartphone app (versus a reader) experienced an average 5% (1.2 hours)[i] more time spent in the target glucose range, known as Time in Range (TIR). The free-of-charge FreeStyle LibreLink app enables FreeStyle Libre and FreeStyle Libre 2 system users to receive glucose readings from a small sensor worn on the back of the upper arm, directly to compatible smartphones.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 28,2021

Significant improvement in increasing Time In Range and reducing hypoglycemia among people equipped with Diabeloop DBLG1

Today, Diabeloop presents data1 from about 1,000 patients equipped with DBLG1 System with Accu-Chek Insight insulin pump in Germany. One of the main insights unveiled is an overall Time in optimal glucose Range (70-180 mg/dL) of 73.4% for the whole cohort of patients.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Sep 29,2021

Diabetes Reversal Leader Virta Health Appoints New Executives to Leadership Team and Board of Directors

Virta Health, the type 2 diabetes reversal leader, announced a series of senior leadership appointments aimed at expanding the reach of its virtual metabolic clinic and taking diabetes reversal mainstream. 

View Analyst & Ambassador Comments
Go to original news
Sep 29,2021

Nemaura Medical Launches Beta Version of Its Metabolic Health Program

Nemaura Medical, Inc., a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announces the beta launch of MiBoKo, a new metabolic health program utilizing a noninvasive glucose sensor along with an AI mobile application.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Sep 29,2021

Insulet to Announce Third Quarter 2021 Financial Results on November 4, 2021

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced plans to release its financial results for the third quarter of 2021 on November 4, 2021 after the close of the financial markets. In connection with the release, management will host a conference call that day at 4:30 p.m. (Eastern Time).

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES